Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Malignant Melanoma

  Free Subscription


1 Ann Surg Oncol
1 Br J Cancer
2 Br J Dermatol
1 Cancer
1 Cancer Lett
1 Eur J Dermatol
2 J Am Acad Dermatol
1 J Biol Chem
2 J Invest Dermatol
1 J Surg Oncol
2 Melanoma Res
2 Oncogene
1 Oncol Rep
1 Proc Natl Acad Sci U S A

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    Ann Surg Oncol

  1. VREELAND TJ, Clifton GT, Hale DF, Chick RC, et al
    A Phase IIb Randomized Controlled Trial of the TLPLDC Vaccine as Adjuvant Therapy After Surgical Resection of Stage III/IV Melanoma: A Primary Analysis.
    Ann Surg Oncol. 2021 Feb 27. pii: 10.1245/s10434-021-09709.
    PubMed         Abstract available

    Br J Cancer

  2. YAO S, Janku F, Subbiah V, Stewart J, et al
    Phase 1 trial of ADI-PEG20 plus cisplatin in patients with pretreated metastatic melanoma or other advanced solid malignancies.
    Br J Cancer. 2021 Mar 5. pii: 10.1038/s41416-020-01230.
    PubMed         Abstract available

    Br J Dermatol

  3. PEREZ M, Chakraborty A, Lau LS, Mohammed NBB, et al
    Melanoma-associated glycosyltransferase GCNT2 as an emerging biomarker and therapeutic target.
    Br J Dermatol. 2021 Mar 3. doi: 10.1111/bjd.19891.
    PubMed         Abstract available

  4. EL SHAROUNI MA, Varey AHR, Witkamp AJ, Ahmed T, et al
    Predicting sentinel node positivity in melanoma patients: external validation of a risk-prediction calculator (the MIA nomogram) using a large European population-based patient cohort.
    Br J Dermatol. 2021 Mar 3. doi: 10.1111/bjd.19895.
    PubMed         Abstract available


  5. BANDER ED, Yuan M, Carnevale JA, Reiner AS, et al
    Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies.
    Cancer. 2021 Mar 2. doi: 10.1002/cncr.33459.
    PubMed         Abstract available

    Cancer Lett

  6. MA Y, Wang L, He F, Yang J, et al
    LACTB suppresses melanoma progression by attenuating PP1A and YAP interaction.
    Cancer Lett. 2021 Mar 3. pii: S0304-3835(21)00101.
    PubMed         Abstract available

    Eur J Dermatol

  7. MILLAN-ESTEBAN D, Garcia-Casado Z, Manrique-Silva E, Viros A, et al
    Distribution and clinical role of KIT gene mutations in melanoma according to subtype: a study of 492 Spanish patients.
    Eur J Dermatol. 2021 Mar 1. pii: ejd.2021.3971. doi: 10.1684/ejd.2021.3971.
    PubMed         Abstract available

    J Am Acad Dermatol

  8. CULLISON CR, Tripathi R, Bordeaux JS
    Identifying sociodemographic factors associated with hospitalization following primary excision of cutaneous melanoma.
    J Am Acad Dermatol. 2021 Mar 2. pii: S0190-9622(21)00466.

  9. MILLER RC, Stewart CR, Lipner SR
    Retrospective study of trends in dermatology telemedicine and in-person visits at an academic center during COVID-19.
    J Am Acad Dermatol. 2021;84:777-779.

    J Biol Chem

  10. SAYEDYAHOSSEIN S, Huang K, Li Z, Zhang C, et al
    Pannexin 1 binds beta-catenin to modulate melanoma cell growth and metabolism.
    J Biol Chem. 2021 Feb 26:100478. doi: 10.1016/j.jbc.2021.100478.
    PubMed         Abstract available

    J Invest Dermatol

  11. TIKOO S, Jain R, Tomasetig F, On K, et al
    Amelanotic B16-F10 melanoma compatible with advanced 3-D imaging modalities.
    J Invest Dermatol. 2021 Mar 3. pii: S0022-202X(21)00156.

  12. LANG UE, Torres R, Cheung C, Vladar EK, et al
    Ciliation index is a useful diagnostic tool in challenging spitzoid melanocytic neoplasms.
    J Invest Dermatol. 2020 Jan 21. pii: S0022-202X(20)30038.
    PubMed         Abstract available

    J Surg Oncol

  13. HUI JYC, Burke E, Broman KK, Marmor S, et al
    Surgeon decision-making for management of positive sentinel lymph nodes in the post-Multicenter Selective Lymphadenectomy Trial II era: A survey study.
    J Surg Oncol. 2021;123:646-653.
    PubMed         Abstract available

    Melanoma Res

  14. KOHTAMAKI LM, Hernberg M, Jaakkola M, Makela S, et al
    BRAF inhibitor treatment is feasible in the oldest-old advanced melanoma patients.
    Melanoma Res. 2021 Mar 5. pii: 00008390-900000000-99047.
    PubMed         Abstract available

  15. MOSCHOS SJ, Eroglu Z, Khushalani NI, Kendra KL, et al
    Targeting the IL-2 inducible kinase in melanoma; a phase 2 study of ibrutinib in systemic treatment-refractory distant metastatic cutaneous melanoma: preclinical rationale, biology, and clinical activity (NCI9922).
    Melanoma Res. 2021;31:162-172.
    PubMed         Abstract available


  16. RAWAT V, Malvi P, Della Manna D, Yang ES, et al
    PSPH promotes melanoma growth and metastasis by metabolic deregulation-mediated transcriptional activation of NR4A1.
    Oncogene. 2021 Mar 5. pii: 10.1038/s41388-021-01683.
    PubMed         Abstract available

  17. SULLIVAN RJ, Flaherty K
    Correction to: MAP kinase signaling and inhibition in melanoma.
    Oncogene. 2021 Mar 3. pii: 10.1038/s41388-021-01716.

    Oncol Rep

  18. URANOWSKA K, Kalic T, Valtsanidis V, Kitzwogerer M, et al
    Expression of chondroitin sulfate proteoglycan 4 (CSPG4) in melanoma cells is downregulated upon inhibition of BRAF.
    Oncol Rep. 2021;45:1.
    PubMed         Abstract available

    Proc Natl Acad Sci U S A

  19. TENGESDAL IW, Menon DR, Osborne DG, Neff CP, et al
    Targeting tumor-derived NLRP3 reduces melanoma progression by limiting MDSCs expansion.
    Proc Natl Acad Sci U S A. 2021;118.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Malignant Melanoma is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.